410086-27-0

Usage

Uses

Used in Pharmaceutical Industry:
1(2H)-Isoquinolinone,7-fluoro-(9CI) is used as a pharmaceutical compound for its potential biological activities. As a member of the isoquinoline family, it may exhibit therapeutic properties and be utilized in the development of drugs targeting various diseases and conditions.
Used in Agrochemical Industry:
In the agrochemical industry, 1(2H)-Isoquinolinone,7-fluoro-(9CI) may be employed as a pesticide or herbicide due to its potential biological activities. Its ability to interact with specific biological targets could make it a valuable tool in crop protection and management.
Used in Materials Science:
1(2H)-Isoquinolinone,7-fluoro-(9CI) can be utilized in materials science for the development of new materials with unique properties. Its heterocyclic structure and potential interactions with other molecules make it a promising candidate for creating advanced materials with applications in various industries.

Upstream product

• 928032-28-4 (E)-3-(4-fluorophenyl) acryloyl azide 
• 459-32-5 (E)-4-fluorocinnamic acid 
• 108-05-4 vinyl acetate 
• 1427180-46-8 3-fluoro-N-(pivaloyloxy)benzamide 
• 455-38-9 3-fluorobenzoic acid 
• 1711-07-5 3-fluorobenzoyl chloride 
• 459-32-5 4-fluorocinnamic acid 
• 456-48-4 3-Fluorobenzaldehyde 
• 73261-94-6 N-<(3-fluorophenyl)methylene>-2,2-dimethoxyethanamine 
• 1075-12-3 7-fluoroisoquinoline 
• 1009-00-3 7-fluoroisoquinoline 2-oxide 
• 57381-39-2 2-bromo-5-fluorobenzonitrile 

Downstream Products

• 630422-89-8 1-chloro-7-fluoroisoquinoline 
• 444898-89-9 C₃₅H₂₆FNO₈ 

Relevant academic research and scientific papers

Synthesis of Isoquinolones by Sequential Suzuki Coupling of 2-Halobenzonitriles with Vinyl Boronate Followed by Cyclization

A novel, facile, and expeditious two-step synthesis of 3,4-unsubstituted isoquinolin-1(2H)-ones from a Suzuki cross-coupling between 2-halobenzonitriles and commercially available vinyl boronates followed by platinum-catalyzed nitrile hydrolysis and cyclization is described.

SUBSTITUTED ARYLMETHYLUREAS AND HETEROARYLMETHYLUREAS, ANALOGUES THEREOF, AND METHODS USING SAME

The present invention includes substituted arylmethyl ureas and heteroarylmethyl-ureas, and compositions comprising the same, that can be used to treat or prevent hepatitis B virus (HBV) infections in a patient.

ACTIVATORS OF AUTOPHAGIC FLUX AND PHOSPHOLIPASE D AND CLEARANCE OF PROTEIN AGGREGATES INCLUDING TAU AND TREATMENT OF PROTEINOPATHIES

The present application discloses compounds which are activators of autophagic flux and pharmaceutical compositions comprising said activators. It further discloses use of said compounds and pharmaceutical compositions in the treatment of neurodegenerative diseases, particularly proteinopathies and tauopathies such as Alzheimer's disease. It further discloses methods of enhancing autophagic flux.

Hepatitis C virus inhibitors

Hepatitis C virus inhibitors having the general formula (I) are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

HEPATITIS C VIRUS INHIBITORS

Hepatitis C virus inhibitors having the general formula (I) are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

Hepatitis C Virus Inhibitors

Hepatitis C virus inhibitors having the general formula (I) are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

Rhodium(III)-catalyzed C-H activation/annulation with vinyl esters as an acetylene equivalent

The behavior of electron-rich alkenes in rhodium-catalyzed C-H activation/annulation reactions is investigated. Vinyl acetate emerges as a convenient acetylene equivalent, facilitating the synthesis of sixteen 3,4-unsubstituted isoquinolones, as well as select heteroaryl-fused pyridones. The complementary regiochemical preferences of enol ethers versus enol esters/enamides is discussed.

Hepatitis C Virus Inhibitors

Hepatitis C virus inhibitors having the general formula (I) are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

Hepatitis C Virus Inhibitors

Hepatitis C virus inhibitors having the general formula (I) are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

Hepatitis C Virus Inhibitors

Hepatitis C virus inhibitors having the general formula are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.